BroadOak Capital Partners advised KCAS Bioanalytical and Biomarker Services (“KCAS”) on the sale of the company to Vitruvian. KCAS is a leading contract research organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries. The full press release...
BroadOak Capital Partners invested growth capital in KromaTiD. KromaTiD sells structural genomic products and tech-enabled services to optimize gene editing for research and clinical purposes. The funding will help accelerate the commercialization of its recently launched direction genomic hybridization In-Site and SCREEN products for gene...
Genomenon announced that it has completed a $5.3M financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. The full press release is below. Genomenon Completes $5.3M Financing Round AI-Driven Genomics Company...
BroadOak portfolio company Distributed Bio was acquired by Charles River Laboratories. Distributed Bio is a provider of innovative antibody discovery, engineering, informatics tools, and services for the life sciences research and drug discovery markets. The full press release is below. Charles River Laboratories Acquires Distributed Bio – Establishes...
BroadOak Capital Partners is pleased to announce the addition of Bryan Poltilove to its growth capital investing team, where he serves as a Managing Director. Mr. Poltilove joins BroadOak from Thermo Fisher Scientific and brings with him significant domain and operational expertise. Most recently as...
BroadOak leads the formation and funding of a new ambulatory infusion platform, InFuse Holdings, to build a network of infusion centers throughout the Midwest. Initial funding used to acquire Cincinnati-based Horizon Infusions and provide growth capital for its expansion. The full press release is below. InFuse Holdings...
BroadOak portfolio company Akron Biotech was acquired by Arcline Investment Management. Akron is a provider of GMP-compliant cell-/gene-therapy and engineered tissue products and services. The full press release is below. Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology BOCA RATON, Fla.,...
BroadOak Partners advised Cenetron Diagnostics (“Cenetron”) on the sale of the company to Versiti. Cenetron provides central laboratory services to support global clinical trials for biopharmaceutical, diagnostic, and contract research organizations. The full press release is below. Versiti Acquires Texas-based Cenetron Central Laboratories and Salus IRB to...
BroadOak Capital Partners advised Astero Bio Corporation (“Astero”) on the sale of the company to BioLife Solutions. Astero is a provider of innovative tools that improve the quality of high-value cell and gene therapies. The full press release is below. BioLife Solutions Expands Cell and Gene Therapy...
Reaction Biology Corporation (“RBC”), a BroadOak portfolio company, completes a stock swap transaction whereby RBC acquires all the shares of ProQinase GmbH, an early stage drug discovery company based in Freiburg, Germany. RBC is an early stage drug discovery CRO specializing in biochemical and cell-based...
Stay connected
Partner with BroadOak